D-threo-PDMP

D-threo-PDMP is a potent glucoceramide synthase (GCS) inhibitor, which reduces the glycosphingolipids (such as GM3 and GD3) on the cell surface by inhibiting glycosylation, reduces the total length of the axon plexus and the number of axon branch points, and inhibits neurite growth. D-threo-PDMP inhibits the synthesis of GM3, thereby reducing the adhesion ability of B16 melanoma cells and mimicking the pathological effects of hyperglycemia/TGF-β1. D-threo-PDMP inhibits the synthesis of GD3, thereby protecting liver cells from apoptosis induced by TNF-α. D-threo-PDMP can be used to study diseases related to targeted glycosphingolipid metabolism[1][2][3][4].

Product Specifications

CAS Number

[109836-82-0]

UNSPSC

12352005

Target

Apoptosis; Glucosylceramide Synthase (GCS)

Type

Reference compound

Related Pathways

Apoptosis; Neuronal Signaling

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Cancer; Metabolic Disease; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/d-threo-pdmp.html

Purity

99.50

Solubility

DMSO : 200 mg/mL (ultrasonic)

Smiles

CCCCCCCCCC(N[C@H](CN1CCOCC1)[C@H](O)C2=CC=CC=C2)=O

Molecular Formula

C23H38N2O3

Molecular Weight

390.56

References & Citations

[1]Carmen García-Ruiz, et al. Defective TNF-alpha-mediated hepatocellular apoptosis and liver damage in acidic sphingomyelinase knockout mice. J Clin Invest. 2003 Jan;111 (2) :197-208. |[2]Dong Hoon Kwak, et al. Ganglioside GM3 inhibits the high glucose- and TGF-beta1-induced proliferation of rat glomerular mesangial cells. Life Sci. 2005 Sep 30;77 (20) :2540-51. |[3]Inokuchi J, et al. Effects of D-threo-PDMP, an inhibitor of glucosylceramide synthetase, on expression of cell surface glycolipid antigen and binding to adhesive proteins by B16 melanoma cells. J Cell Physiol. 1989 Dec;141 (3) :573-83. |[4]Hiranita T, et al. Stimulants as specific inducers of dopamine-independent σ agonist self-administration in rats. J Pharmacol Exp Ther. 2013 Oct;347 (1) :20-9.